Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice.
Thiotepa (TT) has long been considered for inclusion in clinical bone marrow transplant (BMT) conditioning regimens in an attempt to prevent allograft rejection and leukemia relapse. These studies have been encouraged by initial murine experiments showing a clear improvement in allogeneic bone marrow engraftment with addition of TT to total body irradiation (TBI) where it was assumed that TT enhances donor-type chimerism via ablation of competing stem cells in the recipient. The aim of the present study was to re-evaluate the hematological toxicity of TT among different stem cell subsets that included primitive cells capable of long-term repopulation and to assess how the combination of TT with TBI influences the development of donor engraftment in both syngeneic (B6-Gpi-1a --> B6-Gpi-1b) and H-2 compatible allogeneic (BALB.B10 --> B6) BMT models. At 24 h after TT (20 mg/kg) the femoral content of different stem cell subsets was determined from the frequency of transient repopulating, and the more primitive cobblestone area-forming, cells (CAFCs) growing in stroma-supported cultures. This assay showed a large TT-induced depletion (2% survival) of early clones developing at day 7 in culture but survival recovered towards normal for later appearing clones developing from more primitive CAFC subsets. The sparing of these primitive stem cells was reflected as undetectable levels of donor marrow repopulation in recipients given TT followed by syngeneic BMT. Addition of TT to TBI did not significantly improve long-term engraftment of syngeneic marrow while this combination had a dramatic effect in allogeneic BMT by preventing allograft rejection. In this respect TT shares similar properties with cyclophosphamide and suggests that the large improvement of allogeneic stem cell engraftment is attributable to the immune suppressive properties of TT rather than to its toxicity against host primitive stem cells.
Down
J D
JD
Groningen Institute for Drug Studies, University of Groningen, The Netherlands.
Westerhof
G R
GR
Boudewijn
A
A
Setroikromo
R
R
Ploemacher
R E
RE
D000477:Alkylating Agents / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D016026:Bone Marrow Transplantation / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011828:Radiation Chimera; D013852:Thiotepa / Q000494:pharmacology* / Q000633:toxicity; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D014916:Whole-Body Irradiation
D000477:Alkylating Agents; D013852:Thiotepa